Helus Pharma reports FY2026 results with APPROACH Phase 3 enrollment above 88%

Cybin Inc. (d/b/a Helus Pharma) (HELP) — Cybin, operating as Helus Pharma, released fiscal-year 2026 results and a business update, reporting that enrollment in its pivotal Phase 3 APPROACH study of HLP003 for adjunctive major depressive disorder had passed 88%, keeping a topline readout on track for Q4 2026.

Phase 2 data previously showed roughly a 23-point MADRS improvement at 12 months after two doses. The update reinforces the company's positioning as a late-stage psychedelics developer following its 2026 Nasdaq uplisting and rebrand.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.